AB SCIEX acquires Eksigent liquid chromatography business

AB SCIEX, a global player in the life science analytical technologies market, announced Feb. 16 that it has acquired the liquid chromatography business of Dublin, Calif.-based Eksigent Technologies

Register for free to listen to this article
Listen with Speechify
CONCORD, Ontario—AB SCIEX, a global player in the life science analytical technologies market, announced Feb. 16 that it has acquired the liquid chromatography business of Dublin, Calif.-based Eksigent Technologies. According to the official news release about the deal, "This acquisition significantly strengthens AB SCIEX's position in liquid chromatography, which is a key technology used frequently in a broad range of life science applications such as protein biomarker research, drug discovery and basic research."

Among the technologies AB SCIEX is acquiring are Eksigent's NanoLC-Ultra System for proteomics, the cHiPLC-nanoflex System for protein peptide separations and the ExpressHT-Ultra HPLC System for LC/MS studies of pharmacokinetics and drug metabolism. AB SCIEX calls Eksigent "a leading provider of advanced low-flow, fluid delivery technologies."

Approximately 50 employees in Eksigent's research and development, manufacturing, sales and related functions will continue to operate at its California headquarters.

This acquisition gives AB SCIEX a significant position for entry into the liquid chromatography market because it will now be able to provide instrumentation and consumables used to separate, identify and quantify very small quantities of molecules based on their chemical properties and to couple them with mass spectrometry instruments to form complete workflow solutions.

"This acquisition demonstrates the strategy for growth that resulted in the creation of AB SCIEX," says Andy Boorn, president of AB SCIEX. "Eksigent's portfolio of HPLC technologies is among the most innovative within the industry and is extremely complementary to our market-leading mass spectrometry systems. We expect to further develop and broaden the use of these technologies for a variety of life science applications."

"AB SCIEX is focused on providing some of the most innovative technologies and integrated workflow solutions for the life science industry. This acquisition addresses a broad range of applications, such as the rapidly growing peptide quantitation market, by further enabling breakthrough performance and ease of use through the combination of Eksigent's leading-edge liquid chromatography technology and AB SCIEX's best-in-class mass spectrometers," adds Laura Lauman, who is also president of AB SCIEX. "The use of liquid chromatography continues to grow, and we are looking forward to working with the Eksigent team to create additional value for our customers around the world."

This follows after the news just over two weeks earlier that AB SCIEX was launching as a new company dedicated to life science analytical technologies. The company had previously had a more than 20-year history under an Applied Biosystems/MDS Analytical Technologies joint venture.

AB SCIEX considers itself the global market leader in mass spectrometry, and intends to utilize its new operating structure—as well as its newly acquired product line from Eksigent—to increase speed to market in developing solutions and expanding service and support that will enable the scientific community to continue using mass spectrometry for a, increasingly broad range of applications.

"The vision that led to the creation of AB SCIEX is that this integrated company will be able to shape the future of mass spectrometry in ways far greater than what we have already achieved as the market leader in this industry," according to Lauman. "By bringing our former joint venture together as a single operating company, AB SCIEX will be able to create a new level of energy, achieve greater customer focus and satisfaction, and further accelerate innovation to keep pace with the dynamic needs of the life science industry."

"AB SCIEX is the go-to company for the most robust, rugged and reliable analytical tools available in the marketplace today," Boorn adds. "When scientists think about AB SCIEX, I want them to think about first: First in innovation, first in new technologies, first to bring solutions to help them solve their problems. Our continuous advancements in developing leading-edge technologies enable us to make meaningful contributions to the health and safety of people around the world."

AB SCIEX is, in turn, a part of Danaher Corp., which completed its acquisition of AB SCIEX on Feb. 1.

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN July 2024 Magazine Issue

Latest Issue  

• Volume 20 • Issue 4 • July 2024

July 2024

July 2024 Issue